NEU 411
Alternative Names: NEU-411Latest Information Update: 27 Nov 2024
Price :
$50 *
At a glance
- Originator Neuron23
- Class Antiparkinsonians; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 19 Nov 2024 Neuron23 in-licenses Digital Biomarker and Device technology from Roche
- 08 Nov 2024 Neuron23 plans phase II NEULARK trial in Parkinson's disease (Early-stage disease) in January 2025 (PO) (NCT06680830)
- 02 Jun 2024 Neuron23 completes a phase I clinical trials in Parkinson's disease (In volunteers) in New Zealand (PO) (NCT05755191)